PureTech Health plc (LON:PRTC)
139p+0.29%
Spriggl Score: Moderate— see the number + sub-scores with a free Spriggl account
Last 30 trading days
Spriggl AI Verdict
“Seaport stake offers tangible value floor; wholly-owned pipeline adds binary upside to this deep-value holding.”
Sign up free to read the full investment thesis, bull case, bear case and what to watch.
About PureTech Health plc
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. It is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody,…
- Sector:
- Healthcare
- Industry:
- Biotechnology
- Market Cap:
- £334.9M
Recent dividends
No recent dividends recorded.
Get the full Spriggl analysis — free
Sign up for a free Spriggl account to unlock the full Spriggl Score breakdown, screener, watchlist, and AI investment analysis on PureTech Health plc and 1,600+ UK and US stocks.
Start free